Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 4/2005

01.04.2005 | For debate

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1

verfasst von: M. A. Nauck, A. El-Ouaghlidi

Erschienen in: Diabetologia | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Excerpt

Glucagon-like peptide 1 (GLP-1) and its derivatives have generated considerable interest [1]. GLP-1 has the potential to normalise glucose concentrations in patients with type 2 diabetes; however, this peptide hormone is degraded and eliminated from the circulation too rapidly to be of therapeutic value. The initial step of proteolytic cleavage and inactivation is mediated by dipeptidyl peptidase-IV (DPP-IV), following which, only 10–15% of the peptide remains in its intact, biologically active form during the continuous infusion of GLP-1 [2]. DPP-IV inhibitors reverse this effect, increasing circulating levels by a factor of 4–6 during the infusion of exogenous GLP-1 [3], thus providing the rationale for their use in diabetes therapy. Phase II studies have shown that DPP-IV inhibitors can lower HbA1c levels by approximately 1%, thus confirming their therapeutic potential [4]. …
Literatur
1.
Nauck MA, Meier JJ, Creutzfeldt W (2003) Incretins and their analogues as new antidiabetic agents. Drug News Perspect 16:413–422
2.
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Host JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44:1126–1131
3.
Deacon CF, Hughes TE, Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764–769
4.
Åhren B, Gomis R, Standl E, Mills D, Schweizer A (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874–2880
5.
Nauck MA, Baller B, Meier JJ (2004) Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53[Suppl 3]:S190–S196
6.
Hansotia T, Baggio LL, Delmeire D et al (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326–1335
7.
Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324–1331
8.
Pauly RP, Demuth HU, Rosche F et al (1999) Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48:385–389
9.
Reimer MK, Holst JJ, Åhren B (2002) Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717–727
10.
Larsen MO, Rolin B, Ribel U et al (2003) Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass. Exp Diabetes Res 4:93–105
11.
Dardik B, Valentin M, Schwartzkopf C et al (2003) NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys (abstract 1292-P). Diabetes 52[Suppl 1]:A322
12.
Åhren B, Gomis R, Mills D, Schweizer A (2004) The DPP-IV inhibitor, LAF237, improves glycemic control in patients with Type 2 diabetes (T2DM) inadequately treated with metformin (abstract 354-OR). Diabetes 53[Suppl 2]:A83
13.
Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307
14.
Kjems LL, Holst JJ, Vølund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386
15.
Nauck MA, Niedereichholz U, Ettler R et al (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273:E981–E988
16.
Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719–2725
17.
Kolterman OG, Buse JB, Fineman MS et al (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082–3089
18.
Juhl CB, Hollingdal M, Sturis J et al (2002) Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424–429
19.
El-Ouaghlidi A, Rehring E, Schweizer A, Holmes D, Nauck MA (2003) The dipeptidyl peptidase IV inhibitor LAF237 does not accentuate reactive hypoglyaemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects (abstract 507-P). Diabetes 52[Suppl 1]:A118
20.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628–2635
21.
Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR (2004) Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27:1335–1342
22.
Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355–362
23.
El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Holmes D, Nauck MA (2004) Reduced increments in total glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in plasma after a single dose of the dipeptidyl peptidase-4 inhibitor LAF237 before an oral glucose load in healthy subjects (abstract 786). Diabetologia 47[Suppl 1]:A284
24.
Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CH (1996) The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 45:1335–1341
25.
Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21:619–670
26.
Sudre B, Broqua P, White RB et al (2002) Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51:1461–1469
27.
Herman GA, Zhao P-L, Dietrich B et al (2004) DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics (abstract 353-OR). Diabetes 53[Suppl 2]:A82
Metadaten
Titel
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
verfasst von
M. A. Nauck
A. El-Ouaghlidi
Publikationsdatum
01.04.2005
Erschienen in
Diabetologia / Ausgabe 4/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1704-8

Weitere Artikel der Ausgabe 4/2005

Diabetologia 4/2005 Zur Ausgabe

Short communication

Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test

Short communication

Fat distribution is strongly associated with plasma glucose levels and diabetes in Thai adults—the InterASIA study

Article

High normal 2-hour plasma glucose is associated with insulin sensitivity and secretion that may predispose to type 2 diabetes

Article

A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice

For debate

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

Short communication

Increased aortic stiffness is persistent in type 1 diabetic women: a follow-up study

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise